Login to Your Account



FDA Notes Suicides with Forest, Nycomed COPD Drug Daxas

By Donna Young


Tuesday, April 6, 2010
WASHINGTON — The FDA's concerns over suicides linked to Forest Laboratories Inc.'s chronic obstructive pulmonary disease (COPD) drug Daxas (roflumilast) had investors only somewhat worried Monday, with shares slipping just slightly. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription